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Leydig cell testicular tumors are a rare cause of precocious pseudopuberty in boys.
Surgery is the main therapy and shows good overall prognosis. The physical signs of
precocious puberty are expected to disappear shortly after surgical removal of the mass.
We report two children, 7.5 and 7.7 year-old boys, who underwent testis-sparing surgery
for a Leydig cell testicular tumor causing precocious pseudopuberty. During follow-
up, after an immediate clinical and laboratory regression, both boys presented signs
of precocious puberty and ultimately developed central precocious puberty. They were
successfully treated with gonadotropin-releasing hormone (GnRH) analogs. Only six other
cases have been described regarding the development of central precocious puberty
after successful treatment of a Leydig cell tumor causing precocious pseudopuberty.
Gonadotropin-dependent precocious puberty should be considered in children treated for
a Leydig cell tumor presenting persistent or recurrent physical signs of puberty activation.
In such cases, therapy with GnRH analogs appears to be the most effective medical
treatment.
Keywords: Leydig cell tumor, precocious pseudopuberty, true precocious puberty, GnRH stimulation test, GnRH
analogs
INTRODUCTION
Central precocious puberty is caused by premature activation of the hypothala-
mic–pituitary–gonadal axis, while precocious pseudopuberty results from peripheral over
production of sex steroids (1–9). Leydig cell tumors are the most common hormone-secreting
testicular tumors and are an unusual cause of precocious pseudopuberty in boys (5, 9). Surgical
excision of the mass is usually curative with regression of signs, nevertheless the development of
central precocious puberty after surgery can occasionally be observed (4–9). We report two boys
who developed true precocious puberty after surgical treatment of a Leydig cell tumor of the testis
that presented peripheral precocious puberty.
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CASE REPORT
Patient 1
The patient was first evaluated at our Paediatric Endocrinology
Department. Aged 7.5 years with a history of progressive appear-
ance of secondary sexual characteristics for 4months. He had
pubic hair (Tanner stage PH2), enlarged testicular volume (Tanner
stage G2: left testis 4mL, right testis 6mL) and an accelerated
growth velocity. Pubertal stage has been performed according
to Tanner-Marshall method on physical examination (1). Fam-
ily history of precocious puberty was negative. His height was
134.6 cm (90th–97th centile, 1.63 SDS) and his body mass index
(BMI) was 17.7 (1.17 SDS). Serum concentrations of follicle-
stimulating hormone (FSH) and luteinizing hormone (LH) were
suppressed, also after administration of gonadotropin-releasing
hormone (GnRH) stimulation test. FSH and LH were measured
by chemiluminescent immunoassay. His biological data at diag-
nosis are shown in Table 1. Tumor markers [alpha-fetoprotein
(AFP), β-human chorionic gonadotropin (β-HCG)] were within
the normal range. Adrenal function was normal. Ultrasound of
the testis demonstrated an inhomogeneous hypoechogenic tumor
located at the upper pole of the enlarged right testis (measuring
18.8mm 12mm 14mm). Surgical enucleation of the testic-
ular mass was performed. Histological examination revealed a
Leydig cell tumor. Inhibin was expressed immunohistochem-
ically and the index of proliferation (Ki67–MIB1) was <3%
(Figure 1). Following surgery, levels of plasma sexual hormones
rapidly returned to the normal prepuberal range and there was
no sexual progression. Four months later, the patient presented
with increased pubic hair (Tanner stage PH2) and increased
bilateral testicular volume (Tanner stage G3: left and right testis
8mL). Recurrent erections and ejaculations were observed. Bone
TABLE 1 | Hormonal assessment of boys with Leydig cell tumors at presentation and after surgery.
Pt Age
(years)
Bone age
G-P
(years)
Testosterone
(ng/dL)
Basal LH
(mUI/mL)
Basal FSH
(mUI/mL)
Peak LHa
(mUI/mL)
Peak FSHa
(mUI/mL)
Surgery Testosterone values
after surgery
(ng/dL)
Reference
Pt 1 7.5 10.8 156 2 1.3 0.15 1.1 Testis-sparing 21
Pt 2 7.7 10 183 1.5 0.8 1.2 0.9 Testis-sparing 19
1 6.0 12 270 2.6 1.5 5.8 3.3 Orchidectomy 34 (4)
2 6.5 13 887 1.2 1 1.4 1.1 Orchidectomy 20.2 (5)
3 6.6 12 312 <0.07 <0.3 0.17 0.67 Orchidectomy 24 (6)
4 7.0 12.5 144 Low Low Low Low Orchidectomy 64 (7)
5 9.0 13.5 268 <0.1 <0.3 NR NR Orchidectomy 37 (8)
6 8.0 12 148 0.2 1.4 NR NR Testis-sparing NR (9)
Pt, patient; G-P, Greulich and Pyle; LH, luteinizing hormone; FSH, follicle-stimulating hormone; NR, not reported.
aMaximum value after GnRH test (0.1mg Relefact LHRH), testosterone normal value <20 ng/dL.
FIGURE 1 | (A) Hematoxylin–eosin (H/E), original magnification 10x. Well-circumscribed nodule with solid/lobular architecture. (B) H/E, original magnification 200x.
Neoplasm characterized by solid growth of polygonal cells with eosinophilic granular cytoplasm. No evidence of mitosis and/or necrosis. (C) IHC polymeric
horseradish peroxidase (HRP)-linker antibody, original magnification 200x. Neoplastic cells are positive (brown) for gonadal hormone a-inhibin immunostain. (D) IHC
polymeric horseradish peroxidase (HRP)-linker antibody, original magnification 200x. Neoplastic cells are negative for vimentin immunostain.
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TABLE 2 | Hormonal assessment of boys with secondary central precocious puberty after surgical treatment of Leydig cell tumors.
Pt Age
(years)
Testosterone
(ng/dL)
Basal LH
(mUI/mL)
Basal FSH
(mUI/mL)
Peak LHa
(mUI/mL)
Peak FSHa
(mUI/mL)
Therapy Testosterone value
after therapy (ng/dL)
Reference
Pt 1 7.8 178 3.2 4.5 24.1 10 Triptorelin 14
Pt 2 8.0 210 3.8 4.8 19.4 10.7 Triptorelin 18
1 6.5 280 12 11 57 19 Cyproterone acetate 34 (4)
2 6.7 141.3 11 5.5 22 13.5 Decapeptyl 20.2 (5)
3 7.7 47 0.67 4.53 20.48 12.73 leuprorelin acetate 16 (6)
4 7.1 201 NR NR Pubertal Pubertal leuprolide acetate prepubertal (7)
5 9.05 High 11.9 11.3 25.1 15.3 NR NR (8)
6 8.2 245 2.6 3.4 15.2 5.7 Triptorelin <3 (9)
Pt, patient; LH, luteinizing hormone; FSH, follicle-stimulating hormone; NR, not reported.
aMaximum value after GnRH test (0.1mg Relefact LHRH), testosterone normal value <20 ng/dL.
age was accelerated to 12.5 years. Ultrasonographic examinations
ruled out testicular tumor recurrence and brain magnetic res-
onance imaging (MRI) excluded a tumor of the hypothalamus
or pituitary gland. The patient showed a pubertal response to
GnRH stimulation test and the hormonal values are reported in
Table 2. Therefore, non-organic central precocious puberty was
diagnosed. Treatment with triptorelin (3.75mg every 28 days) was
started, resulting in clinical and laboratory regression; normal val-
ues of testosterone and normal, basal, and GnRH stimulated FSH
and LH values were observed. At the last follow-up (2 years from
the beginning of triptorelin therapy), the patient still continues
treatment without adverse effects.
Patient 2
The patient (aged 7.7 years) was evaluated because of progres-
sive appearance of pubic hair and an accelerated growth velocity
during the previous 6months. He presented pubic hair (Tanner
stage PH2) and an increased testicular volume (Tanner stage
G2: right testis 4mL, left testis 5mL). Both testes were homo-
geneous and had no palpable masses. The penis was 12.5 cm
long (10). Family history of precocious puberty was negative.
His height was 140.2 cm (>97th centile, 2.31 SDS) and his BMI
was 16.54 (0.62 SDS). His hormonal data indicated precocious
pseudopuberty (seeTable 1). Tumormarkers (AFP, β-HCG) were
within the normal range and adrenal function was normal. Ultra-
sound demonstrated an inhomogeneous hyperechogenic focal
lesion located at the lower pole of the enlarged left testis (mea-
suring 17mm 11.8mm 12mm). Complete resection of the
testicular mass was performed and the histological investigation
revealed a Leydig cell tumor with immunohistochemical features
of benignity. Testosterone serum levels declined to normal values
(Table 1). Three months after surgery, the patient once again pre-
sented with increased pubic hair and increased bilateral testicular
volume (Tanner stage G3: left and right testis 9mL). The patient
manifested increased erections and ejaculations. X-ray examina-
tion revealed a bone age of 12 years. Brain MRI ruled out a tumor
of the hypothalamus or pituitary gland and ultrasound excluded a
recurrence of the testicular mass. His hormonal values confirmed
central precocious puberty (Table 2). Treatment with triptorelin
(3.75mg depot injections every 28 days) was started (Table 2).
After 2months, we observed clinical regression of physical signs.
Currently, he continues therapy without adverse effects.
DISCUSSION
Leydig cell tumors are sex cord stromal tumors that arise from
Leydig cells that produce testosterone (4, 9). Testicular tumors
are very rare during childhood and represent only 1% of all
pediatric solid tumors (11). Leydig cell tumors represent 3–6%
of testicular masses in prepuberal males, even though they are
the most common hormone-secreting testicular tumors (5, 7).
Less than 25% have been described in boys aged between 5 and
10 years. These aremostly unilateral and benign although bilateral
tumors have been described in 3–10% of cases and about 10%
of the reported cases evolved into malignant neoplasms (5, 11).
The clinical presentation of Leydig tumors is characterized by iso-
sexual precocious pseudopuberty caused by increased production
of androgens, mostly testosterone, and low gonadotropin levels.
These patients develop secondary sexual characteristics in the
absence of hypothalamic–pituitary activation (4–9). Previously,
treatment for these lesions was a radical orchiectomy with lym-
phadenectomy when regional lymph nodes were involved (11).
Early diagnosis of Leydig cell tumors allowed us to use conserva-
tive surgery as a first-line treatment (12). In the literature, several
cases of males with Leydig cell tumors that developed isosex-
ual precocious pseudopuberty are reported. In particular, Olivier
et al. described a new case of a Leydig cell tumor in a boy and
reported 23 other cases of boys with diagnosis of gonadotropin-
independent precocious puberty secondary to a Leydig cell tumor
from 1999 to 2012 (8). A similar prevalence of tumors between the
right and left testeswas observed and in all patients the histological
analysis showed a Leydig cell tumor. (5, 6, 8).
Between 1998 and 2014, another 13 cases of boys with a Ley-
dig cell tumor and precocious pseudopuberty were described (9,
13–22). In one case, the Leydig cell tumor had histological and
immunohistochemical features of malignancy (16). The molec-
ular analysis revealed a somatic activating mutation of the LH-
receptor (replacement of aspartic acid with histidine at position
578: Asp578His) in only one patient (19). D’Alessio et al. reported
a case of a metachronous contralateral Leydig cell tumor (22).
Testis-sparing surgery was the first-line treatment (9, 13, 15, 17,
18, 20–22).
In our cases, the Leydig cell tumor had the typical clini-
cal and hormonal characteristics of gonadotropin-independent
precocious puberty (low LH and FSH with high testosterone).
A testosterone-producing testicular tumor was identified as the
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cause of sexual precocity. It is interesting to underline that our
patients developed gonadotropin-dependent precocious puberty,
associated with accelerated growth and bone maturation, after
surgical therapy. Only six other cases of central precocious
puberty after initial treatment of a Leydig cell tumor, causing
precocious pseudopuberty, have been described. This evolution
may be more common than expected and should be consid-
ered in children with persistent or recurrent symptoms of pre-
cocious puberty after successful therapy. This phenomenon has
also been observed in children with congenital adrenal hyper-
plasia, familial male precocious puberty, and McCune Albright
syndrome (7). Although the pathogenesis of central precocious
puberty after precocious pseudopuberty remains unknown, it
is probable that early maturation of the hypothalamic GnRH
pulse generator is caused by exposure to high concentrations of
testosterone.
GnRH analog therapy is themost effective treatment for central
precocious puberty. Progressive pubertal development should be
documented over a 3- to 6-month period before GnRH analog
treatment is initiated as this therapy is not always necessary. A
surveillance period is useful to demonstrate the persistence of
central stimulation and to detect patients that might benefit from
treatment (3). However, in our cases, both patients presented with
an accelerated skeletal maturation and rapidly progressive puber-
tal development (Tanner stage G3, erections and ejaculations)
associated with a pubertal response to GnRH stimulation test.
We, therefore, decided to eliminate the observational period and
immediately start GnRH analog treatment.
In Tables 1 and 2, we summarized the clinical and hormonal
features of our two cases and of the other six cases previously
described.
In 1986, Criscuolo et al. presented a case of a 6-year-old
boy with precocious pseudopuberty due to a Leydig cell tumor.
After surgery, the hormonal profile progressively returned to the
prepuberal range and sexual precocity disappeared. Six months
later, the patient developed central precocious puberty, and
was treated with cyproterone acetate (4). The second case was
described in 2001: a 6.5-year-old boy with high levels of 17-
hydroxyprogesterone that initially led to the erroneous diagno-
sis of congenital adrenal hyperplasia, and unilateral testicular
enlargement due to a Leydig tumor. His physical findings and lab-
oratory values did not improve with hydrocortisone but resolved
after orchidectomy. Three months later, he presented with central
precocious puberty and was initially treated with medroxypro-
gesterone and cyproterone acetate, and then with GnRH analogs
(5). Kiepe et al. described a 6.6-year-old boy with sexual pseudo-
precocity caused by a somatic activating mutation of the LH-
receptor. One year after surgery, he developed a gonadotropin-
dependent precocious puberty (6). Two other cases have been
described in the literature, one in 2011 (7) and the other in
2012 (8).
The last case described (9) is an 8-year-old boy with isosex-
ual precocity with gonadotropin hormone-independent testos-
terone hypersecretion. Ultrasound and histopathological analysis
revealed a Leydig cell tumor. After surgery, testosterone levels
remained high and hormonal examination showed gonadotropin-
dependent precocious puberty. A long-acting GnRH analog was
started and sexual precocity was suppressed (9).
CONCLUSION
In conclusion, beside our two patients, only six other cases of
central precocious puberty after successful treatment of a Ley-
dig cell tumor, causing precocious pseudopuberty, have been
described.Wewould like to underline that, even though it is a rare
condition, gonadotropin-dependent precocious puberty should
be considered in patients who have been successfully treated for a
Leydig cell tumor andwho present persistent or recurrent physical
signs of sexual precocity. This can be caused by high levels of
testosterone and other sex steroids that can trigger gonadotropin-
dependent puberty.
GnRH analog treatment appears to be the most effective medi-
cal therapy available for progressive central precocious puberty.
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